NEWAMSTERDAM PHARMA CO NV (NAMS) Stock News

USA - Nasdaq - NASDAQ:NAMS - NL00150012L7 - Common Stock

35.905 USD

-2.42 (-6.33%)

Last: 12/3/2025, 11:20:05 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NAMS Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

8 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

13 days ago - By: The Motley Fool - Mentions: HTFL VZ CDTX PHVS ...

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million

13 days ago - By: The Motley Fool - Mentions: CDTX HTFL PHVS OLMA

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer

a month ago - By: Benzinga

Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)

3 months ago - By: Benzinga

Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts

26 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26 days ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Zacks Investment Research - Mentions: SPRY

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

a month ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

a month ago - By: Zacks Investment Research - Mentions: MDGL

Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates

a month ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

a month ago - By: Zacks Investment Research - Mentions: CORT

NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy?

2 months ago - By: CARISTO DIAGNOSTICS

Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation

2 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

2 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

3 months ago - By: Menarini Industrie Farmaceutiche Riunite

Evropská agentura pro léčivé přípravky (EMA) přijala od skupiny Menarini Group žádost o registraci přípravků Obicetrapib a Obicetrapib/Ezetimib pro léčbu dospělých pacientů s primární hypercholesterolemií (heterozygotní familiární a nefamiliární) nebo

3 months ago - By: Menarini Industrie Farmaceutiche Riunite

Заявки на получение регистрационного удостоверения обицетрапиба и обицетрапиба/эзетимиба от Menarini Group, принятые для рассмотрения Европейским агентством по лекарственным средствам (EMA) для лечения взрослых с первичной гиперхолестеринемией

3 months ago - By: Menarini Industrie Farmaceutiche Riunite

Wnioski o pozwolenie na dopuszczenie do obrotu leków Obicetrapib i Obicetrapib/Ezetimibe firmy Menarini Group zostały przyjęte do rozpatrzenia przez Europejską Agencję Leków (EMA) w zakresie leczenia dorosłych z pierwotną hipercholesterolemią

3 months ago - By: Menarini Industrie Farmaceutiche Riunite

Die Zulassungsanträge der Menarini Group für Obicetrapib und Obicetrapib/Ezetimibe zur Behandlung von Erwachsenen mit primärer Hypercholesterinämie (heterozygote familiäre und nicht-familiäre Form) oder gemischter Dyslipidämie wurden von der Europäischen

3 months ago - By: Menarini Industrie Farmaceutiche Riunite

Les demandes d'autorisation de mise sur le marché de l'obicetrapib et de l'obicetrapib/ézétimibe de Menarini Group ont été acceptées pour examen par l'Agence européenne des médicaments (EMA) pour le traitement des adultes atteints d'hypercholestérolémie

3 months ago - By: Menarini Industrie Farmaceutiche Riunite

Aceptadas las solicitudes de autorización de comercialización de obicetrapib y obicetrapib/ezetimiba

3 months ago - By: Menarini Industrie Farmaceutiche Riunite

Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the European Medicines Agency (EMA) for the Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial)

3 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

3 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

3 months ago - By: Piramal Pharma Solutions

Piramal Pharma Solutions und NewAmsterdam Pharma investieren in einen spezialisierten Produktionsbereich, um die Herstellungskapazitäten fester oraler Darreichungsformen am Piramal-Standort in Sellersville, Pennsylvania, zu erweitern

3 months ago - By: Piramal Pharma Solutions

Piramal Pharma Solutions et NewAmsterdam Pharma investissent dans une unité dédiée pour améliorer les capacités de production de dosages solides oraux sur le site de Piramal à Sellersville, en Pennsylvanie.

3 months ago - By: Piramal Pharma Solutions

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

4 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

4 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

4 months ago - By: Zacks Investment Research - Mentions: ASRT

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results